Burris K.D., Molski, T.F., Xu, C., Ryan, E, Tottori, K., Kikuchi, T., Yocca, F.D. and Molinoff, P.B. (2002) Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. The Journal of Pharmacology and Experimental Therapeutics, 302, 381-389. doi:10.1124/jpet.102.033175

has been cited by the following article:

• TITLE: Withdrawal seizure associated with high dosage of aripiprazole and fluoxetine: a case report

  AUTHORS: Jian-An Su, Shih-Yong Chou, Ching-Shu Tsai, Tai-Hsin Hung

  KEYWORDS: Aripiprazole; High Dosage; Withdrawal Seizure

  JOURNAL NAME: Open Journal of Psychiatry, Vol.1 No.2, July 12, 2011

  ABSTRACT: Aripiprazole, a third-generation antipsychotic, has been considered to have a high safety profile and rare withdrawal symptoms. We reported the case of a schizophrenic patient with a significant obsession, who was treated with a high dosage of aripiprazole and fluoxetine. Generalized tonic-clonic seizure occurred two days after abruptly stopping these two medications. Gradually tapering aripiprazole is suggested in clinical practice, especially when using a high dosage.